AER002: meta-analysis of COVID-19 studies

0 0.5 1 1.5+ All studies -6% 1 36 Improvement, Studies, Patients Relative Risk RCTs -6% 1 36 Late -6% 1 36 AER002 for COVID-19 c19early.org December 2025 FavorsAER002 Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ outSMART-LC Peluso (DB RCT) -6% 1.06 [0.96-1.18] PASC 24 (n) 12 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.25 Late treatment -6% 1.06 [0.96-1.18] 24 (n) 12 (n) 6% higher risk All studies -6% 1.06 [0.96-1.18] 24 (n) 12 (n) 6% higher risk 1 AER002 COVID-19 study c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.25 Effect extraction pre-specified(most serious outcome) Favors AER002 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ outSMART-LC Peluso (DB RCT) -6% 1.06 [0.96-1.18] PASC 24 (n) 12 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.25 Late treatment -6% 1.06 [0.96-1.18] 24 (n) 12 (n) 6% higher risk All studies -6% 1.06 [0.96-1.18] 24 (n) 12 (n) 6% higher risk 1 AER002 COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.25 Effect extraction pre-specified(most serious outcome) Favors AER002 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ outSMART-LC Peluso (DB RCT) -6% 1.06 [0.96-1.18] PASC 24 (n) 12 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.25 Late treatment -6% 1.06 [0.96-1.18] 24 (n) 12 (n) 6% higher risk All studies -6% 1.06 [0.96-1.18] 24 (n) 12 (n) 6% higher risk 1 AER002 COVID-19 long COVID result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.25 Favors AER002 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ outSMART-LC Peluso (DB RCT) -6% 1.06 [0.96-1.18] PASC 24 (n) 12 (n) Improvement, RR [CI] Treatment Control AER002 COVID-19 outcomes c19early.org December 2025 Favors AER002 Favors control